Holen Sie sich die Stockscreener-App
21.25
13.95%
-3.525
Handel nachbörslich:
21.25
Schlusskurs vom Vortag:
$24.77
Offen:
$24.78
24-Stunden-Volumen:
141.73K
Relative Volume:
1.28
Marktkapitalisierung:
$451.43M
Einnahmen:
$41,000
Nettoeinkommen (Verlust:
$-325.66M
KGV:
-1.0847
EPS:
-19.5907
Netto-Cashflow:
$-165.54M
1W Leistung:
-5.08%
1M Leistung:
-17.49%
6M Leistung:
+66.30%
1J Leistung:
+75.82%
1-Tages-Spanne:
$20.89
$25.48
1-Wochen-Bereich:
$20.89
$27.75
52-Wochen-Spanne:
$7.65
$45.00
Lyell Immunopharma Inc Stock (LYEL) Company Profile
Firmenname
Lyell Immunopharma Inc
Sektor
Branche
Telefon
650 695-0677
Adresse
201 HASKINS WAY, SOUTH SAN FRANCISCO
Compare LYEL vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LYEL
Lyell Immunopharma Inc
|
21.25 | 526.32M | 41,000 | -325.66M | -165.54M | -19.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Lyell Immunopharma Inc Stock (LYEL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-09 | Eingeleitet | Citizens | Mkt Outperform |
| 2025-12-09 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-10-30 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-06-27 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-08-28 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-11-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-11-11 | Herabstufung | Goldman | Buy → Neutral |
| 2022-10-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-07-12 | Eingeleitet | BofA Securities | Buy |
| 2021-07-12 | Eingeleitet | Goldman | Buy |
| 2021-07-12 | Eingeleitet | JP Morgan | Overweight |
| 2021-07-12 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Lyell Immunopharma Inc Aktie (LYEL) Neueste Nachrichten
Lyell Immunopharma: Q4 Earnings Snapshot - theheraldreview.com
Lyell Immunopharma 2025 Annual Report: Advancing Next-Generation CAR T-Cell Therapies for Cancer Treatment - Minichart
Lyell Immunopharma 2025 Financial Results: Annual Loss of $274.4MNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Lyell Immunopharma: Fourth Quarter Financial Results Overview - Bitget
Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results - The Manila Times
LYEL: Pivotal CAR T-cell trials show strong efficacy, with key data updates and solid funding ahead - TradingView
Lyell Immunopharma Appoints Smital Shah as Chief Financial and Business Officer Effective March 2026 - Minichart
Lyell Immunopharma (NASDAQ:LYEL) Shares Gap UpShould You Buy? - MarketBeat
Lyell Immunopharma (NASDAQ:LYEL) Now Covered by Citizens Jmp - MarketBeat
Lyell Immunopharma closes $50M equity tranche, names new CFO - Investing.com Nigeria
Lyell Immunopharma closes $50M equity tranche, names new CFO By Investing.com - Investing.com Canada
Lyell Immunopharma, Inc. Appoints Smital Shah as Chief Business Officer and Principal Financial Officer, Effective March 9, 2026 - marketscreener.com
Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer - Stock Titan
Citizens initiates Lyell Immunopharma stock at outperform, $34 target - Investing.com South Africa
Citizens initiates Lyell Immunopharma stock at outperform, $34 target By Investing.com - Investing.com UK
Citizens Initiates Coverage on LYEL with Market Outperform Ratin - GuruFocus
HC Wainwright & Co. Maintains Lyell Immunopharma (LYEL) Neutral Recommendation - MSN
Take Profit: Will Lyell Immunopharma Inc benefit from rate cutsTrade Volume Summary & Accurate Intraday Trading Signals - baoquankhu1.vn
Fund Flows: Is Lyell Immunopharma Inc impacted by rising ratesIndex Update & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Breakouts Watch: Is Lyell Immunopharma Inc stock trending bullishJuly 2025 Weekly Recap & Long-Term Capital Growth Ideas - baoquankhu1.vn
Lyell Immunopharma Inc expected to post a loss of $2.37 a shareEarnings Preview - TradingView
Lyell Immunopharma (LYEL) to Release Earnings on Tuesday - Defense World
Lyell Immunopharma Advances GCC19CART Trial in Metastatic Colorectal Cancer: What Investors Should Know - TipRanks
LYEL.O Technical Analysis & Stock Price Forecast - Intellectia AI
LYEL Technical Analysis & ETF Price Forecast - Intellectia AI
Lyell Immunopharma Announces Participation in March Investor Conferences - GlobeNewswire
What is the long term forecast for Lyell Immunopharma Inc. stockEarnings Recap Report & Risk Managed Investment Strategies - mfd.ru
How Lyell Immunopharma Inc. stock reacts to global recession fearsPortfolio Risk Report & Weekly Return Optimization Plans - mfd.ru
What’s the MACD signal for Lyell Immunopharma Inc.Portfolio Value Summary & Free Verified High Yield Trade Plans - mfd.ru
Is Lyell Immunopharma Inc. stock gaining market shareWeekly Trend Recap & Stock Market Timing Techniques - mfd.ru
Can Lyell Immunopharma Inc. stock beat market expectations this quarterJuly 2025 Movers & Reliable Intraday Trade Alerts - mfd.ru
Will Lyell Immunopharma Inc. stock deliver shareholder valueMarket Trend Review & Fast Gaining Stock Strategy Reports - mfd.ru
Lyell Immunopharma (NASDAQ:LYEL) Shares Gap DownHere's Why - MarketBeat
Lyell Immunopharma, Inc. (NASDAQ:LYEL) Short Interest Up 28.0% in January - MarketBeat
Can Lyell Immunopharma Inc. maintain sales growthJuly 2025 Outlook & Fast Moving Stock Trade Plans - mfd.ru
Institution Moves: Can Lyell Immunopharma Inc maintain sales growth2025 Retail Activity & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
LYEL Should I Buy - Intellectia AI
Lyell starts first-of-its-kind CAR-T trial; New coalition aims to boost European biotechs - BioPharma Dive
Lyell Immunopharma (NASDAQ:LYEL) COO Stephen Hill Sells 1,236 Shares - MarketBeat
Lyell Immunopharma (NASDAQ:LYEL) Insider Sells $39,084.69 in Stock - MarketBeat
Insider Selling: Lyell Immunopharma (NASDAQ:LYEL) CEO Sells 7,455 Shares of Stock - MarketBeat
Lyell Immunopharma (NASDAQ:LYEL) Trading Up 7.3%Should You Buy? - MarketBeat
Lyell Immunopharma Announces Initiation Of Patient Dosing In First-Of-Its-Kind Phase 3 Car T-Cell Clinical Trial - TradingView
Lyell Immunopharma, Inc. (Lyell) announced that dosing has begun for patients with aggressive large B-cell lymphoma in a groundbreaking Phase 3 clinical trial. - Bitget
Inside the first head-to-head CAR T cancer trial testing Lyell’s ronde-cel - Stock Titan
Sentiment Review: Is Lyell Immunopharma Inc. stock gaining market shareJuly 2025 Selloffs & Smart Allocation Stock Reports - mfd.ru
Insider Selling: Lyell Immunopharma (NASDAQ:LYEL) CEO Sells 438 Shares of Stock - MarketBeat
Is Lyell Immunopharma Inc. stock trending bullishBreakout Watch & Daily Profit Maximizing Tips - mfd.ru
Lyell Immunopharma (LYEL) grants CSO 50,000 options, small share sale - Stock Titan
Pullback Watch: Is Lyell Immunopharma Inc stock trending bullishJuly 2025 Setups & Daily Profit Focused Screening - baoquankhu1.vn
How do insiders feel about American Express CompanyIPO Watch & Technical Analysis for Trade Confirmation - baoquankhu1.vn
Finanzdaten der Lyell Immunopharma Inc-Aktie (LYEL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.18%
0.28%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):